Education
About Us
Working with TipRanks
Follow Us
Moderna (DE:0QF)
XETRA:0QF
0QF Stock Chart & Stats
€42.82
-€2.54(-5.63%)
At close: 4:00 PM EST
€42.82
-€2.54(-5.63%)
Day’s Range― - ―
52-Week Range€19.37 - €50.57
Previous CloseN/A
Volume96.78K
Average Volume (3M)22.37K
Market Cap
€18.02B
Enterprise Value€20.06B
Total Cash (Recent Filing)€5.80B
Total Debt (Recent Filing)€1.92B
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Apr 30, 2026EPS Estimate
-1.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.82
Shares Outstanding394,939,420
10 Day Avg. Volume18,505
30 Day Avg. Volume22,370
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.33
Price to Sales (P/S)5.90
P/FCF Ratio-5.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€31.07Price Target Upside-27.44% Downside
Rating ConsensusHold
Number of Analyst Covering18
EPS Forecast (FY)-5.65
Revenue Forecast (FY)€1.78B
Bulls Say, Bears Say
Bulls Say
Clinical Trial ReadoutAnalyst notes a positive late-stage readout for intismeran in adjuvant melanoma could diversify revenue away from COVID and become a meaningful new growth driver.
Cost Reduction And Cash BurnReduced operating spending and improved working capital demonstrate the company's ability to lower cash burn and support a multi-year path toward breakeven.
Royalty Elimination And Revenue VisibilityRemoval of future royalty obligations on infectious disease vaccines improves revenue visibility and allows fuller attribution of vaccine and pipeline value.
Bears Say
Appellate Litigation RiskAn appeal over government‑contractor immunity could extend legal uncertainty and leave contingent liabilities that may require additional payments depending on higher court rulings.
Patent Litigation ExposureMultiple active lawsuits, including claims around delivery technology and a new booster design suit, increase the chance of infringement findings and potential damages or royalty obligations.
Post-marketing Study BurdenA likely requirement to run a large post‑approval efficacy study in older adults could raise program costs and complicate commercialization of the flu vaccine.
Moderna News
0QF FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was €19.37 and its highest was €50.57 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is €18.02B.
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Apr 30, 2026 which is in 52 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on Feb 13, 2026. The company reported -€1.816 earnings per share for the quarter, beating the consensus estimate of -€2.189 by €0.373.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Overvalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -1.75.
How many shares outstanding does Moderna have?
Moderna has 394,939,420 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -€1.816 in its last earnings report, beating expectations of -€2.189. Following the earnings report the stock price went up 14.108%.
Which hedge fund is a major shareholder of Moderna?
Currently, no hedge funds are holding shares in DE:0QF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Moderna Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€31.07 (-27.44% Downside)
€31.07 (-27.44% Downside)
Blogger Sentiment
Bullish
DE:0QF Sentiment 83%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $703.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 53%
Bearish news 47%
Bearish news 47%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.11%
12-Months-Change
Fundamentals
Return on Equity
-28.87%
Trailing 12-Months
Asset Growth
-12.76%
Trailing 12-Months
Company Description
Moderna
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
0QF Company Deck
0QF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights meaningful operational and commercial progress — notably strong MNEXT Spike launch, substantial cost reductions (operating expenses down 30%, cost of sales down 41%, R&D down 31%), improved losses and a healthy cash balance — alongside multiple clinical and commercial catalysts (fully enrolled late‑stage trials, strategic partnerships, international filings). Major risks include the FDA refusal to file for the flu vaccine, continued net losses and cash runoff toward 2026, and reliance on event‑driven readouts and international approvals for growth. Overall, the company demonstrated strong execution and cost discipline but faces material regulatory and timing risks that temper near‑term visibility.View all DE:0QF earnings summaries0QF Revenue Breakdown
61.68% U.S.
2.73% Europe
35.60% Rest of World
0QF Stock 12 Month Forecast
Average Price Target
€31.07
▼(-27.44% Downside)
Technical Analysis
Ionis Pharmaceuticals
―
Protagonist Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
―
Options Prices
Currently, No data available
---